Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Rituximab launched in Switzerland

Nov. 28, 1997

First anticancer monoclonal antibody approved by FDA

Nov. 27, 1997

Results from Leuvectin trial in kidney cancer patients reported

Nov. 26, 1997

Phase I trial of multiple-dose IDEC-C2B8 in NHL

Nov. 24, 1997

International phase III trial of Maxamine in malignant melanoma

Nov. 18, 1997

Evidence that Theratope elicits an antitumor cellular immune response presented

Nov. 18, 1997

FDA approves Intron A for non-Hodgkin's lymphoma

Nov. 12, 1997

AntiVirals to acquire ImmunoTherapy and its late-stage cancer vaccine

Nov. 7, 1997

Phase I trials begin on TNT in glioma patients

Nov. 6, 1997

Novopharm Biotech cleared for phase I trials of melanoma immunotherapy

Oct. 30, 1997

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...